Unleashing success in pharma: An interview with Elena Bushberg, Executive Director of Olainfarm, by the Global Pharmaceutical Leaders’ Club
In the ever-changing world of the pharmaceutical industry, companies’ leaders face relentless challenges head-on to success. In the interview, we spoke with Elena Bushberg, Executive Director of Olainfarm, one of the leading pharmaceutical companies in the Eurasia region, about her views on the current situation in the Eurasia region and the future of the industry.
In the interview with Elena Bushberg, we discussed the following questions:
– What are the priorities for your company in Eurasia?
– What trends having the most impact on pharmaceutical markets in the countries of Eurasia do you highlight for your company?
– What planned regulatory changes may affect the development of the pharmaceutical markets in Eurasia?
What are the priorities for your company in the Eurasia region?
Olainfarm is driven by a profound commitment to deliver high quality therapies in the fields of neurology, cardiology, urology, and other therapeutic areas. Our ultimate goal is to enhance the health and improve the quality of life for our patients.
In our pursuit of supporting healthcare professionals, pharmacists, and patients, we are continuously expanding our product portfolio. As the leading pharmaceutical company in the Baltics, we strive to make significant investments in research and development, modernize our facilities, increase our production capacity, and embrace digitalisation processes. These efforts enable us to deliver the essential treatments and therapies needed for the well-being and improved health outcomes of our patients. By staying at the forefront of innovation and technology, we are able to meet the evolving needs of the healthcare industry and make a positive impact on the lives of individuals across the region.
As a socially responsible enterprise, Olainfarm goes beyond its core mission by actively engaging in education initiatives. We are dedicated to making a positive impact in the communities we serve, particularly in Central Asia. Through our support of local initiatives and social projects like “Cosmic Calmness” in Uzbekistan, we strive to change the culture of health awareness and empower individuals to improve their quality of life and life expectancy.
What trends having the most impact on pharmaceutical markets in the countries of the Eurasian region do you highlight for your company?
The Eurasian region is experiencing rapid economic growth and technological advancements. We are witnessing a significant transformation in diagnostics and treatment practices, with a growing number of individuals becoming more conscious of their health. That is a positive trend as it ensures that people can live healthier and longer lives improving their quality and wellbeing. As a key player in the healthcare industry, we are actively contributing to these changes in our respective fields.
In Uzbekistan, we have observed a strong emphasis on population health, with the government and ministries prioritizing access to medicines and healthcare services for the people. These emerging trends have a profound impact on the development of the pharmaceutical market and play a crucial role in shaping our investment decisions related to these countries.
We embrace the opportunities presented by this dynamic region, recognizing the potential for collaboration and innovation. By aligning our strategies with the evolving healthcare landscape, we aim to enhance patient outcomes and contribute to the overall well-being of communities. Our dedication to delivering high-quality therapies and our commitment to sustainable growth are at the forefront of our decision-making process.
What planned regulatory changes may affect the development of the pharmaceutical markets in the Eurasian region?
We closely monitor changes in pricing regulations in all countries we operate, as overregulated markets usually experience stagnation, which lack positive dynamics.
Serialization is also one of our key areas of focus. In fact, Olainfarm was the first European company to successfully transition to serialized product shipments to Uzbekistan. We are confident that we will be well-prepared to ensure timely delivery of serialized products to Kazakhstan and Kyrgyzstan as well.
Furthermore, we pay close attention to developments within the Eurasian Economic Union (EAEU), as regulatory changes within this economic community have a significant impact on the pharmaceutical markets of this region.